Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins

Kiyoshi Tachikawa, Oliver Schröder, Gerhard Frey, Steven P. Briggs, Takashi Sera

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

We describe a facile method to activate or repress transcription of endogenous genes in a quantitative and specific manner by treatment with designed regulatory proteins (DRPs), in which artificial transcription factors (ATFs) are fused to cell-penetrating peptides (CPPs). Penetration of DRPs into cells is mediated by an N-terminal CPP fused to a nuclear localization signal; a DNA-binding domain and a transactivation domain follow. The DNA-binding domain was targeted to the vascular endothelial growth factor (VEGF)-A gene. An agonist DRP was rapidly taken up by cells and transported to the nucleus; soon after, the cells began transcribing the gene and secreting VEGF-A protein in a dose-dependent manner. Multiple copies of a short oligopeptide derived from a minimal transactivation domain of human β-catenin was stronger than VP-16. The SRDX domain from the plant transcription factor, SUPERMAN, changed the DRP to a hypoxia-induced antagonist of VEGF-A. DRPs combine many of the potential benefits of transgenes with those of recombinant proteins.

Original languageEnglish
Pages (from-to)15225-15230
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number42
DOIs
Publication statusPublished - Oct 19 2004
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Cell-Penetrating Peptides
Genes
Proteins
Transcriptional Activation
Transcription Factors
Catenins
Nuclear Localization Signals
Oligopeptides
DNA
Etoposide
Transgenes
Recombinant Proteins

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins. / Tachikawa, Kiyoshi; Schröder, Oliver; Frey, Gerhard; Briggs, Steven P.; Sera, Takashi.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 42, 19.10.2004, p. 15225-15230.

Research output: Contribution to journalArticle

Tachikawa, Kiyoshi ; Schröder, Oliver ; Frey, Gerhard ; Briggs, Steven P. ; Sera, Takashi. / Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins. In: Proceedings of the National Academy of Sciences of the United States of America. 2004 ; Vol. 101, No. 42. pp. 15225-15230.
@article{356fffee716f4da2a82993401b29a56a,
title = "Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins",
abstract = "We describe a facile method to activate or repress transcription of endogenous genes in a quantitative and specific manner by treatment with designed regulatory proteins (DRPs), in which artificial transcription factors (ATFs) are fused to cell-penetrating peptides (CPPs). Penetration of DRPs into cells is mediated by an N-terminal CPP fused to a nuclear localization signal; a DNA-binding domain and a transactivation domain follow. The DNA-binding domain was targeted to the vascular endothelial growth factor (VEGF)-A gene. An agonist DRP was rapidly taken up by cells and transported to the nucleus; soon after, the cells began transcribing the gene and secreting VEGF-A protein in a dose-dependent manner. Multiple copies of a short oligopeptide derived from a minimal transactivation domain of human β-catenin was stronger than VP-16. The SRDX domain from the plant transcription factor, SUPERMAN, changed the DRP to a hypoxia-induced antagonist of VEGF-A. DRPs combine many of the potential benefits of transgenes with those of recombinant proteins.",
author = "Kiyoshi Tachikawa and Oliver Schr{\"o}der and Gerhard Frey and Briggs, {Steven P.} and Takashi Sera",
year = "2004",
month = "10",
day = "19",
doi = "10.1073/pnas.0406473101",
language = "English",
volume = "101",
pages = "15225--15230",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "42",

}

TY - JOUR

T1 - Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins

AU - Tachikawa, Kiyoshi

AU - Schröder, Oliver

AU - Frey, Gerhard

AU - Briggs, Steven P.

AU - Sera, Takashi

PY - 2004/10/19

Y1 - 2004/10/19

N2 - We describe a facile method to activate or repress transcription of endogenous genes in a quantitative and specific manner by treatment with designed regulatory proteins (DRPs), in which artificial transcription factors (ATFs) are fused to cell-penetrating peptides (CPPs). Penetration of DRPs into cells is mediated by an N-terminal CPP fused to a nuclear localization signal; a DNA-binding domain and a transactivation domain follow. The DNA-binding domain was targeted to the vascular endothelial growth factor (VEGF)-A gene. An agonist DRP was rapidly taken up by cells and transported to the nucleus; soon after, the cells began transcribing the gene and secreting VEGF-A protein in a dose-dependent manner. Multiple copies of a short oligopeptide derived from a minimal transactivation domain of human β-catenin was stronger than VP-16. The SRDX domain from the plant transcription factor, SUPERMAN, changed the DRP to a hypoxia-induced antagonist of VEGF-A. DRPs combine many of the potential benefits of transgenes with those of recombinant proteins.

AB - We describe a facile method to activate or repress transcription of endogenous genes in a quantitative and specific manner by treatment with designed regulatory proteins (DRPs), in which artificial transcription factors (ATFs) are fused to cell-penetrating peptides (CPPs). Penetration of DRPs into cells is mediated by an N-terminal CPP fused to a nuclear localization signal; a DNA-binding domain and a transactivation domain follow. The DNA-binding domain was targeted to the vascular endothelial growth factor (VEGF)-A gene. An agonist DRP was rapidly taken up by cells and transported to the nucleus; soon after, the cells began transcribing the gene and secreting VEGF-A protein in a dose-dependent manner. Multiple copies of a short oligopeptide derived from a minimal transactivation domain of human β-catenin was stronger than VP-16. The SRDX domain from the plant transcription factor, SUPERMAN, changed the DRP to a hypoxia-induced antagonist of VEGF-A. DRPs combine many of the potential benefits of transgenes with those of recombinant proteins.

UR - http://www.scopus.com/inward/record.url?scp=6344227879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344227879&partnerID=8YFLogxK

U2 - 10.1073/pnas.0406473101

DO - 10.1073/pnas.0406473101

M3 - Article

C2 - 15475575

AN - SCOPUS:6344227879

VL - 101

SP - 15225

EP - 15230

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 42

ER -